These vegetable-based dental chews received the Seal of Acceptance from the Veterinary Oral Health Council.

FORT WORTH, TX—November 1, 2013 – Virbac Corporation announces that it will now display the highly regarded Seal of Acceptance from the Veterinary Oral Health Council (VOHC) on their C.E.T.^® VEGGIEDENT^® Chews. Both the small and regular sizes of the chews were awarded the Seal of Acceptance in September 2013 after the VOHC reviewed trial data. The seal was awarded to VEGGIEDENT Chews for its ability to protect against tartar (calculus) build up on the teeth of dogs.

FORT WORTH, Texas — Virbac has announced the introduction of palatable RILEXINE^® (cephalexin) Chewable Tablets for Dogs, the first FDA-approved cephalexin designed exclusively for veterinary medicine, to aid veterinarians and pet owners in the treatment of secondary superficial bacterial pyoderma caused by susceptible strains of Staphylococcus pseudintermedius.

FORT WORTH, Texas (June 24, 2013) – Virbac Corporation today announced that Fiona J. McLellan, General Manager Virbac Canada, Inc., has been elected to the position of Chair on the Canadian Animal Health Institute (CAHI) board of directors.

FORT WORTH, Texas (March 11, 2012) – Virbac Corporation today announced that two of its products will be featured in upcoming episodes of the Lifetime Network’s Designing Spaces television show.  One episode will feature a segment on Virbac ANXITANE^® (L-Theanine) Tablets, and a second episode will feature a segment on Virbac C.E.T. chews, oral solutions and toothpastes.

New treatment helps control adrenal gland cortical disease in ferrets with a dissolvable implant.

FORT WORTH, TX—August 10, 2012 – Virbac announces the indexing of SUPRELORIN F Implant, a new, non-surgical treatment for ferrets suffering from adrenal gland cortical disease, delivered via a dissolvable, controlled-release implant.